Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
16,121 stopped studies · 89% state a reason
Over the 16,121 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT02967276 | Clinical Activity of Metformin With High-dose of Dexamethasone in Relapse Multiple Myeloma(METDEXA-MM) | Phase 2 | terminated | Nov 18, 2016 | University of Campinas, Brazil | Recruitment difficulties due to more attractive competing studies. | Enrollment / accrual |
| NCT05006794 | Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as… | Phase 1 | terminated | Aug 16, 2021 | Gilead Sciences | Sponsor decision to terminate | Sponsor / business decision |
| NCT01523171 | Phase II, Open Label, Single Arm Study of SAR302503 In Myelofibrosis Patients Previously…(JAKARTA2) | Phase 2 | terminated | Feb 1, 2012 | Bristol-Myers Squibb | not stated | Not stated |
| NCT03075527 | A Phase 2 Study of Durvalumab in Combination With Tremelimumab in Malignant Pleural… | Phase 2 | terminated | Mar 9, 2017 | Dana-Farber Cancer Institute | Criteria not met for second stage at time of interim analysis | Efficacy / futility |
| NCT03148327 | Astra Zeneca (Immuno Stereotactic Ablative Body Radiotherapy) ISABR Study: Randomized… | Phase 1 / Phase 2 | terminated | May 11, 2017 | Jonsson Comprehensive Cancer Center | Low accrual | Enrollment / accrual |
| NCT03425331 | Biomarkers of Response to Ipilimumab and Nivolumab in First-line NSCLC | Phase 2 | terminated | Feb 7, 2018 | Dana-Farber Cancer Institute | Slow accrual, competing studies, and lack of efficacy | Efficacy / futility |
| NCT05875935 | Assessment of Awake Surgery With Electrocorticographic Recordings in the Management of…(ECoG) | N/A | terminated | May 25, 2023 | GCS Ramsay Santé pour l'Enseignement et la Recherche | Medical device defective | Other (stated, no rule matched) |
| NCT05986890 | Roux-en-Y Gastric Bypass Versus Loop Gastrojejunostomy for Malignant Gastric Outlet… | N/A | terminated | Aug 14, 2023 | Corewell Health West | The study was terminated early due to poor participant accrual, resulting in inadequate enrollment… | Enrollment / accrual |
| NCT06028373 | A Study of ATG-031 in Advanced Solid Tumors or B-cell Non-Hodgkin Lymphomas | Phase 1 | terminated | Sep 8, 2023 | Antengene Biologics Limited | The study was terminated because of sponsor's development strategy change | Sponsor / business decision |
| NCT06060561 | Genetic Testing to Improve Management of Patients Undergoing Breast Biopsy | — | suspended | Sep 29, 2023 | Mayo Clinic | on hold for analysis | Other (stated, no rule matched) |
| NCT06364696 | A Study to Find a Suitable Dose of ASP4396 in Adults With Solid Tumors | Phase 1 | terminated | Apr 15, 2024 | Astellas Pharma Inc | Company's strategic decision | Sponsor / business decision |
| NCT07152821 | Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory,…(BATTMAN) | Phase 3 | terminated | Sep 3, 2025 | Canadian Cancer Trials Group | Pharmaceutical Sponsor discontinued trial financial support | Funding |
| NCT07441330 | Evaluation of Data Obtained From Three Common Imaging Techniques: Positron Emission… | N/A | terminated | Feb 27, 2026 | GCS Ramsay Santé pour l'Enseignement et la Recherche | difficulty in including patients | Other (stated, no rule matched) |
| NCT07449481 | A Phase II Clinical Study of Utidelone and Bevacizumab With or Without Etoposide in… | Phase 2 | withdrawn | Mar 4, 2026 | Tianjin Medical University Cancer Institute and Hospital | Following an evaluation by the investigator, the study has been terminated due to exceptional… | Investigator |
| NCT03384836 | Propranolol Hydrochloride and Pembrolizumab in Treating Patients With Stage IIIC-IV… | Phase 1 / Phase 2 | suspended | Dec 27, 2017 | Roswell Park Cancer Institute | interim Analysis | Efficacy / futility |
| NCT04698564 | Utility of Hyperpolarized 13C-pyruvate Metabolic Magnetic Resonance Imaging | Phase 2 | terminated | Jan 7, 2021 | University of Maryland, Baltimore | "Study terminated due to institutional resource constraints, including limited availability of… | Safety / toxicity |
| NCT06528093 | A Study to Find a Suitable Dose of BI 765883 and to Test Whether it Helps People With… | Phase 1 | terminated | Jul 30, 2024 | Boehringer Ingelheim | not stated | Not stated |
| NCT03969446 | Pembrolizumab and Decitabine With or Without Venetoclax in Treating Patients With Acute… | Phase 1 | suspended | May 31, 2019 | City of Hope Medical Center | Accrual goal Met | Enrollment / accrual |
| NCT04469504 | Preoperative Prehabilitation for Sarcopenic Patients Prior to Pancreatic Surgery for…(PSOAS) | N/A | terminated | Jul 14, 2020 | University Hospital, Lille | The study was terminated prematurely due to patient inclusion difficulties. | Other (stated, no rule matched) |
| NCT05400122 | Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming… | Phase 1 | suspended | Jun 1, 2022 | David Wald | Drugs unavailable | Other (stated, no rule matched) |
| NCT05828589 | A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies | Phase 1 | terminated | Apr 25, 2023 | BeOne Medicines | This decision is due to a company business decision with strategy change on the BGB-21447… | Safety / toxicity |
| NCT06538389 | High Cannabidiol Plant Extract (BRC-001) to Improve Aromatase Inhibitor-Induced… | Phase 2 | suspended | Aug 5, 2024 | City of Hope Medical Center | Accrual goal met | Enrollment / accrual |
| NCT02200042 | Radiation Therapy vs. Observation Following Gemcitabine and Cisplatin for Inoperable… | Phase 3 | terminated | Jul 25, 2014 | NRG Oncology | not stated | Not stated |
| NCT03874858 | A Study of Full Treatment-free Remission in Patients With Chronic Myeloid Leukemia(DANTE) | Phase 2 | terminated | Mar 14, 2019 | Novartis Pharmaceuticals | Sponsor decision: The primary endpoint of the core/TF1 was achieved, and the sample size of… | Safety / toxicity |
| NCT04158141 | Testing the Addition of Targeted Radiation Therapy to Surgery and the Usual Chemotherapy… | Phase 3 | terminated | Nov 8, 2019 | NRG Oncology | Permanent Administrative Closure | Other (stated, no rule matched) |
| NCT04933695 | A Study of Sotorasib (AMG 510) in Participants With Stage IV NSCLC Whose Tumors Harbor a…(CodeBreaK201) | Phase 2 | terminated | Jun 22, 2021 | Amgen | Futility | Efficacy / futility |
| NCT05067777 | Massage for Prostate Cancer-Related Fatigue (mPROSTATE)(mPROSTATE) | Phase 2 | terminated | Oct 5, 2021 | University of Utah | Lack of Funding | Funding |
| NCT05199311 | Carfilzomib, Iberdomide (CC-220) and Dexamethasone (KID) in Transplant Eligible Multiple… | Phase 1 / Phase 2 | suspended | Jan 20, 2022 | Hackensack Meridian Health | Temporary Hold Pending Amendment Approval | Other (stated, no rule matched) |
| NCT05451849 | A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer | Phase 1 / Phase 2 | terminated | Jul 11, 2022 | TCR2 Therapeutics | No participants were enrolled in Phase 2 as Phase I was terminated early due to the lack of a clear… | Enrollment / accrual |
| NCT05478837 | Genetically Modified Cells (KIND T Cells) for the Treatment of HLA-A*0201-Positive…(PNOC018) | Phase 1 | terminated | Jul 28, 2022 | University of California, San Francisco | Logistical issues | Other (stated, no rule matched) |
| NCT06158100 | Venetoclax in Combination With Azacitidine (VEN/AZA) Followed by Donor Lymphocyte… | Phase 1 | terminated | Dec 6, 2023 | Antonio M Jimenez Jimenez | Funding Sponsor decision due to review of efficacy data from other trials involving investigational… | Efficacy / futility |
| NCT06470451 | Confirmatory Study of Topical HyBryte™ vs. Placebo for the Treatment of CTCL(FLASH2) | Phase 3 | terminated | Jun 24, 2024 | Soligenix | The Data Monitoring Committee conducted an interim analysis and recommended that the study be… | Efficacy / futility |
| NCT06685068 | A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors | Phase 1 / Phase 2 | terminated | Nov 12, 2024 | Genmab | Genmab has decided to terminate the GEN1286 program due to an unfavorable benefit-risk profile not… | Other (stated, no rule matched) |
| NCT07121244 | A Phase 1 Study of 68Ga-R11228 and 177Lu-R11228 in Breast Cancer | Phase 1 | terminated | Aug 13, 2025 | Radionetics Oncology | Sponsor decision | Sponsor / business decision |
| NCT02347228 | Evaluate Safety, Tolerability, PK, Preliminary Clinical Activity of OB318 in Patients… | Phase 1 | terminated | Jan 27, 2015 | Oneness Biotech Co., Ltd. | This decision is based on a strategic company decision to discontinue development of this program… | Sponsor / business decision |
| NCT02728388 | Photodynamic Therapy for Benign Dermal Neurofibromas- Phase II | Phase 2 | terminated | Apr 5, 2016 | Donald Basel | data analysis unequivocal - requires study methodology re-evaluation | Other (stated, no rule matched) |
| NCT03439046 | Study of the Molecular Features of Postmenopausal Women With HR+ HER2-negative aBC on…(BioItaLEE) | Phase 3 | terminated | Feb 20, 2018 | Novartis Pharmaceuticals | Novartis terminated the trial early because the collected data were sufficient to perform the… | Other (stated, no rule matched) |
| NCT03766126 | Lentivirally Redirected CD123 Autologous T Cells in AML | Phase 1 | terminated | Dec 6, 2018 | University of Pennsylvania | Administrative reasons. | Other (stated, no rule matched) |
| NCT04348643 | Safety and Efficacy of CEA-Targeted CAR-T Therapy for Relapsed/Refractory CEA+ Cancer | Phase 1 / Phase 2 | withdrawn | Apr 16, 2020 | Chongqing Precision Biotech Co., Ltd | The sponsor requested to terminate the study. | Other (stated, no rule matched) |
| NCT07614828 | Exploratory Clinical Study of Neoadjuvant Immunotherapy Combined With Chemotherapy in… | Phase 2 | withdrawn | May 29, 2026 | Eye & ENT Hospital of Fudan University | no participants enrolled | Enrollment / accrual |
| NCT03114319 | Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors | Phase 1 | terminated | Apr 14, 2017 | Novartis Pharmaceuticals | Business reasons and not due to any safety concerns | Safety / toxicity |
| NCT03946423 | BAriaTric Surgery After Breast Cancer Treatment (BATS) | N/A | withdrawn | May 10, 2019 | Masonic Cancer Center, University of Minnesota | Not moving forward with study. | Other (stated, no rule matched) |
| NCT04318327 | BCMA-directed CAR-T Cell Therapy in Adult Patients With Multiple Myeloma | Phase 1 | terminated | Mar 23, 2020 | Novartis Pharmaceuticals | Business decision | Sponsor / business decision |
| NCT04331067 | Neoadjuvant Nivolumab and Chemotherapy in Patients With Localized Triple-negative Breast… | Phase 1 / Phase 2 | terminated | Apr 2, 2020 | Washington University School of Medicine | BMS terminated the study | Other (stated, no rule matched) |
| NCT04568304 | A Study Evaluating Toripalimab Injection Combined With Standard Chemotherapy as a… | Phase 3 | withdrawn | Sep 29, 2020 | Shanghai Junshi Bioscience Co., Ltd. | This study was not conducted | Other (stated, no rule matched) |
| NCT04855136 | Safety and Efficacy of bb2121 (Ide-cel) Combinations in Multiple Myeloma(KarMMa-7) | Phase 1 | terminated | Apr 22, 2021 | Celgene | Business objectives have changed | Sponsor / business decision |
| NCT05403450 | A Study of Tolinapant in Combination With Oral Decitabine/Cedazuridine and Oral… | Phase 1 | terminated | Jun 3, 2022 | Taiho Oncology, Inc. | ASTX660-03 was closed according to protocol as no safe and tolerable dosing for the combination of… | Other (stated, no rule matched) |
| NCT06376253 | A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers | Phase 1 | terminated | Apr 19, 2024 | Novartis Pharmaceuticals | Study termination based on sponsor decision due to lack of tolerability observed with… | Sponsor / business decision |
| NCT06599710 | The Effects of a Food Product Containing Mushroom Extracts (AndoSanTM) in Subjects With… | N/A | withdrawn | Sep 19, 2024 | Mycotech Pharma AS | Insufficient recruitment | Enrollment / accrual |
| NCT07693374 | Chinese Medicinal Component Relieves CIPN and Mitochondria Function | N/A | withdrawn | Jul 9, 2026 | Taiwan Municipal An-Nan Hospital-China Medical University | Initial prep showed that formulation, QC, and cost for high-dose paeonol/Cortex Moutan exceeded the… | Safety / toxicity |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Jul 17, 2026source: clinicaltrials